Last reviewed · How we verify
aminocamptothecin
aminocamptothecin is a Small molecule drug developed by National Cancer Institute (NCI). It is currently in Phase 2 development. Also known as: 9-AC.
Aminocamptothecin is a small molecule used in cancer treatment, specifically studied for various types of cancer including leukemia, lymphoma, and ovarian cancer. It has been investigated in clinical trials as a potential therapeutic agent.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | aminocamptothecin |
|---|---|
| Also known as | 9-AC |
| Sponsor | National Cancer Institute (NCI) |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the Esophagus (PHASE2)
- Aminocamptothecin in Treating Patients With T-cell Lymphoma (PHASE2)
- Aminocamptothecin in Treating Patients With Advanced or Recurrent Kidney Cancer (PHASE2)
- Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum (PHASE2)
- Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma (PHASE2)
- Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer (PHASE2)
- Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity (PHASE1)
- Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- aminocamptothecin CI brief — competitive landscape report
- aminocamptothecin updates RSS · CI watch RSS
- National Cancer Institute (NCI) portfolio CI
Frequently asked questions about aminocamptothecin
What is aminocamptothecin?
Who makes aminocamptothecin?
Is aminocamptothecin also known as anything else?
What development phase is aminocamptothecin in?
Related
- Manufacturer: National Cancer Institute (NCI) — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: 9-AC
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing